Erin Flynt

1.7k total citations
28 papers, 429 citations indexed

About

Erin Flynt is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Erin Flynt has authored 28 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 22 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Erin Flynt's work include Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (8 papers). Erin Flynt is often cited by papers focused on Multiple Myeloma Research and Treatments (27 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (8 papers). Erin Flynt collaborates with scholars based in United States, United Kingdom and Germany. Erin Flynt's co-authors include Anjan Thakurta, Fadi Towfic, María Ortiz, Sarah Gooding, Naser Ansari‐Pour, Michael Amatangelo, Hervé Avet‐Loiseau, Paresh Vyas, Karthik Ramasamy and William E. Pierceall and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Erin Flynt

26 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erin Flynt United States	9	341	312	154	54	39	28	429
Anjla Sood United States	7	385 1.1×	346 1.1×	181 1.2×	28 0.5×	26 0.7×	10	476
Monica Testoni Switzerland	4	230 0.7×	120 0.4×	92 0.6×	87 1.6×	33 0.8×	7	321
Evžen Gregora Czechia	11	218 0.6×	253 0.8×	130 0.8×	22 0.4×	14 0.4×	29	301
Marcus Lefebure United States	6	179 0.5×	152 0.5×	88 0.6×	54 1.0×	56 1.4×	14	288
D Chauhan United States	5	274 0.8×	192 0.6×	151 1.0×	41 0.8×	81 2.1×	7	403
Yongming Zhu China	8	213 0.6×	157 0.5×	68 0.4×	47 0.9×	56 1.4×	15	349
Anuradha Illendula United States	10	317 0.9×	191 0.6×	87 0.6×	20 0.4×	51 1.3×	19	435
Milena Gilestro Italy	10	162 0.5×	174 0.6×	115 0.7×	37 0.7×	38 1.0×	21	227
Romanos Sklavenitis‐Pistofidis United States	8	156 0.5×	145 0.5×	127 0.8×	19 0.4×	81 2.1×	28	297
Vladimir Vorobyev Russia	10	185 0.5×	228 0.7×	137 0.9×	45 0.8×	27 0.7×	39	383

Countries citing papers authored by Erin Flynt

Since Specialization

Citations

This map shows the geographic impact of Erin Flynt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Flynt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Flynt more than expected).

Fields of papers citing papers by Erin Flynt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Flynt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Flynt. The network helps show where Erin Flynt may publish in the future.

Co-authorship network of co-authors of Erin Flynt

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Flynt. A scholar is included among the top collaborators of Erin Flynt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Flynt. Erin Flynt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martin, Nathan, Ethan Thompson, Nicholas Stong, et al.. (2025). Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. British Journal of Haematology. 207(3). 1019–1028. 1 indexed citations

Oekelen, Oliver Van, Michael Amatangelo, Manman Guo, et al.. (2024). Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. Cell Reports Medicine. 5(6). 101584–101584. 7 indexed citations

Flynt, Erin, et al.. (2024). Ktx-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4;14) Multiple Myeloma Preclinical Models. Blood. 144(Supplement 1). 1878–1878. 1 indexed citations

Amatangelo, Michael, Erin Flynt, Nicholas Stong, et al.. (2024). Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma. Cell Reports Medicine. 5(6). 101571–101571. 6 indexed citations

Bird, Sarah, Fernando J. Sialana, Habib Bouguenina, et al.. (2023). P-179 Altered lipid metabolism in IMiD/CELMoD resistant multiple myeloma confers novel and targetable vulnerabilities. Clinical Lymphoma Myeloma & Leukemia. 23. S134–S134. 1 indexed citations

Amatangelo, Michael, Erin Flynt, Nicholas Stong, et al.. (2023). RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects. Blood. 142(Supplement 1). 4665–4665. 2 indexed citations

Stong, Nicholas, Ethan Thompson, Amy Xu, et al.. (2023). Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).. Journal of Clinical Oncology. 41(16_suppl). 8035–8035. 1 indexed citations

Ansari‐Pour, Naser, Mehmet Samur, Erin Flynt, et al.. (2022). Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 141(6). 620–633. 22 indexed citations

Stong, Nicholas, Fadi Towfic, Mehmet Samur, et al.. (2022). The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 141(13). 1574–1583. 21 indexed citations

10.

Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 140(16). 1816–1821. 13 indexed citations

11.

Karagoz, Kübra, Matthew P. Stokes, Fadi Towfic, et al.. (2022). Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. Frontiers in Genetics. 13. 831779–831779. 3 indexed citations

12.

Towfic, Fadi, Erin Flynt, Nicholas Stong, et al.. (2021). Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways. BMC Medical Genomics. 14(1). 295–295. 8 indexed citations

13.

Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2021). Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood. 138(Supplement 1). 458–458.

14.

Thakurta, Anjan, William E. Pierceall, Michael Amatangelo, Erin Flynt, & Amit Agarwal. (2021). Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget. 12(15). 1555–1563. 34 indexed citations

15.

Bauer, Michael, Cody Ashby, Christopher P. Wardell, et al.. (2020). Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 106(3). 736–745. 22 indexed citations

16.

Flynt, Erin, et al.. (2020). Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells. 9(2). 287–287. 42 indexed citations

17.

Gooding, Sarah, Naser Ansari‐Pour, Fadi Towfic, et al.. (2020). Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 137(2). 232–237. 107 indexed citations

18.

Williams, Louis, Eileen M. Boyle, Brian A. Walker, et al.. (2019). Enrichment for copy number alterations and a unique pattern of gene mutations characterize multiple myeloma in elderly patients. Clinical Lymphoma Myeloma & Leukemia. 19(10). e81–e82. 1 indexed citations

19.

Ashby, Cody, Eileen M. Boyle, Ruslana G. Tytarenko, et al.. (2018). Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood. 132(Supplement 1). 110–110. 1 indexed citations

20.

Towfic, Fadi, Mehmet Samur, Erin Flynt, et al.. (2018). A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients. Blood. 132(Supplement 1). 3165–3165. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact